RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mayne Pharma Group Stock

Mayne Pharma Group P/E 2024

Mayne Pharma Group P/E

-2.28

Ticker

MYX.AX

ISIN

AU000000MYX0

WKN

A1C821

As of Nov 5, 2024, Mayne Pharma Group's P/E ratio was -2.28, a -186.04% change from the 2.65 P/E ratio recorded in the previous year.

The Mayne Pharma Group P/E history

Mayne Pharma Group Aktienanalyse

What does Mayne Pharma Group do?

Mayne Pharma Group Ltd. is a leading company in the field of pharmaceutical development and production with manufacturing facilities in Australia and the USA. The company is headquartered in Sydney, Australia and employs over 1,100 employees worldwide. The history of Mayne Pharma dates back to 1845 when the company was founded as a manufacturer of herbal medicine. Over the years, the company has evolved and focused on the pharmaceutical industry, eventually being renamed Mayne Nickless Ltd in 1981. In 2000, the company established its subsidiary Mayne Pharma, specializing in the development and production of generic drugs. Through the acquisition of other companies, Mayne Pharma has expanded its product range and expanded into the USA in 2007. Mayne Pharma focuses on the production of generics and specialty pharmaceuticals, which are marketed worldwide through a variety of distribution channels. The company invests heavily in research and development to develop new products and improve existing ones. The goal is to continuously expand the offering and increase market presence. Through the expansion of the product portfolio and the exploration of new markets, Mayne Pharma has gained a strong position in the pharmaceutical industry in recent years. Mayne Pharma is divided into three divisions: generics, specialty pharmaceuticals, and beauty products. The generics division includes a wide range of prescription generic drugs marketed in the USA, Australia, Canada, and other countries. The company is able to produce cost-effective medications to provide affordable drugs to patients worldwide. The specialty pharmaceuticals division focuses on medications for the treatment of diseases such as cancer, pain, and cardiovascular diseases. Mayne Pharma aims to improve treatment outcomes for patients in these areas and has a promising product development pipeline that includes many innovative therapy options. The beauty products division offers a wide range of high-quality skincare products sold worldwide. This includes skin creams, lip care products, and sunscreens. This division is growing steadily and offers great potential, as it operates not only in the healthcare sector but also in the beauty market. Mayne Pharma has a wide range of products, ranging from medications for everyday ailments to life-saving specialty preparations. Key products include: - Doryx: An oral antibiotic therapy for the treatment of mild to moderate acne. - Lonsurf: A cancer-fighting medication that extends the survival time of advanced colorectal cancer patients. - Kapanol: A long-acting opioid for pain relief in patients with severe pain. - Tolsura: An easy-to-use medication for the treatment of fungal infections, particularly suitable for patients who have difficulty swallowing tablets. - Zenavod: A topical medication for the treatment of vaginal infections. - Golden Glow Sunscreen: A high-quality sunscreen with SPF 50+ that prevents skin irritation and sunburn. In conclusion, Mayne Pharma is a proven and innovative company that focuses on the development and production of generics and specialty pharmaceuticals. With its extensive product range and business activities in key international markets, Mayne Pharma has an outstanding reputation in the pharmaceutical industry. Mayne Pharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Mayne Pharma Group's P/E Ratio

The Price to Earnings (P/E) Ratio of Mayne Pharma Group is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Mayne Pharma Group's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Mayne Pharma Group is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Mayne Pharma Group’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Mayne Pharma Group stock

What is the price-to-earnings ratio of Mayne Pharma Group?

The price-earnings ratio of Mayne Pharma Group is currently -2.28.

How has the price-earnings ratio of Mayne Pharma Group changed compared to last year?

The price-to-earnings ratio of Mayne Pharma Group has increased by -186.04% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Mayne Pharma Group high compared to other companies?

Yes, the price-to-earnings ratio of Mayne Pharma Group is high compared to other companies.

How does an increase in the price-earnings ratio of Mayne Pharma Group affect the company?

An increase in the price-earnings ratio of Mayne Pharma Group would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Mayne Pharma Group affect the company?

A decrease in the price-earnings ratio of Mayne Pharma Group would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Mayne Pharma Group?

Some factors that influence the price-earnings ratio of Mayne Pharma Group are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Mayne Pharma Group pay?

Over the past 12 months, Mayne Pharma Group paid a dividend of 0.78 AUD . This corresponds to a dividend yield of about 17.5 %. For the coming 12 months, Mayne Pharma Group is expected to pay a dividend of 0.78 AUD.

What is the dividend yield of Mayne Pharma Group?

The current dividend yield of Mayne Pharma Group is 17.5 %.

When does Mayne Pharma Group pay dividends?

Mayne Pharma Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mayne Pharma Group?

Mayne Pharma Group paid dividends every year for the past 1 years.

What is the dividend of Mayne Pharma Group?

For the upcoming 12 months, dividends amounting to 0.78 AUD are expected. This corresponds to a dividend yield of 17.5 %.

In which sector is Mayne Pharma Group located?

Mayne Pharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mayne Pharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mayne Pharma Group from 1/27/2023 amounting to 0.777 AUD, you needed to have the stock in your portfolio before the ex-date on 1/18/2023.

When did Mayne Pharma Group pay the last dividend?

The last dividend was paid out on 1/27/2023.

What was the dividend of Mayne Pharma Group in the year 2023?

In the year 2023, Mayne Pharma Group distributed 0 AUD as dividends.

In which currency does Mayne Pharma Group pay out the dividend?

The dividends of Mayne Pharma Group are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mayne Pharma Group

Our stock analysis for Mayne Pharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mayne Pharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.